Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1992)
  2. Solid Tumor Oncology Division (1623)
  3. GSK Faculty (765)
  4. Survivorship Research (637)
  5. Population Sciences Research Program (614)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (414)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2106)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (90)
  5. Editorial (83)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1992)
  2. Solid Tumor Oncology Division (1623)
  3. GSK Faculty (765)
  4. Survivorship Research (637)
  5. Population Sciences Research Program (614)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (101)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (484)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4648)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Individual patient data (IPD) meta-analysis of randomised trials to compare efficacy of second-line fluoropyrimidine-based chemotherapy in advanced biliary tract cancer (BTC)
    Meeting Abstract

    Hyung, J.; Kang, M.; Kim, I.; Kim, P.; Ryoo, B. Y.; Cheon, J.; Ryu, H.; Lee, J. S.; Abou-Alfa, G. K.; Kim, J. W.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Meeting Abstract

    Garmezy, B.; Borad, M.; Lin, C. C.; Chen, L. T.; Perez, C. A.; Kato, S.; Tam, B.; Severson, P.; Quah, C. S.; Harding, J. J.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma
    Meeting Abstract

    Makker, V.; Lee, J. Y.; Oh, D. Y.; Oaknin, A.; Puvvada, S. D.; Cecchi, F.; McEwen, R.; Michelini, F.; Meric-Bernstam, F.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non-small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd)
    Meeting Abstract

    Smit, E. F.; Felip, E.; Uprety, D.; Nagasaka, M.; Nakagawa, K.; Paz-Ares, L.; Pacheco, J.; Li, B. T.; Planchard, D.; Baik, C. S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Real-world practices and physician perspectives on biomarker testing and treatment patterns in patients with locally advanced unresectable or metastatic (La/m) gastric/gastroesophageal junction (G/GEJ) adenocarcinoma in the US
    Meeting Abstract

    Lewis, K.; Fuldeore, R.; Braun, S.; Gourgioti, G.; Lambert, A.; Thomason, G.; Bernacki, K.; Yang, J.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial
    Meeting Abstract

    Loriot, Y.; Pant, S.; Witt, O.; Reardon, D. A.; Doi, T.; Qin, S.; Tabernero, J.; Iyer, G.; Massard, C.; Arnold, D.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial
    Meeting Abstract

    Viteri, S.; Felip, E.; Griesinger, F.; Garassino, M. C.; Sakai, H.; Le, X.; Veillon, R.; Smit, E. F.; Raskin, J.; Thomas, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK plus ) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
    Meeting Abstract

    Solomon, B. J.; Drilon, A.; Lin, J. J.; Bazhenova, L.; Goto, K.; De Langen, J.; Kim, D. W.; Wolf, J.; Springfeld, C.; Popat, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01
    Meeting Abstract

    Johnson, M. L.; Jänne, P. A.; Goto, Y.; Yoh, K.; Lee, S. H.; Paz-Ares, L.; Besse, B.; Novello, S.; Hayashi, H.; Kim, D. W.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study
    Meeting Abstract

    Wasan, H. S.; Harding, J. J.; Fan, J.; Oh, D. Y.; Choi, H. J.; Kim, J. W.; Chang, H. M.; Bao, L.; Sun, H.; Macarulla, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save